• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Endocare

Endocare

Endocan Corp ENDO

Last Price$0.01Day Change (%)-5.00%
Open Price$0.02Day Change ($)0.00
Day Range0.01–0.0252-Week Range0.01–0.05

As of Mon 5/4/2015 1:58:00 PM | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Vernalis and Tris Pharma receive FDA approval of NDA for Tuzistra™ XR (codeine polistirex and chlorpheniramine polistirex)

    Vernalis and Tris Pharma receive FDA approval of NDA for Tuzistra™ XR (codeine polistirex and chlorpheniramine polistirex)

  2. Research and Markets: Laparoscopic Devices - Global Strategic Business Report 2015: US Dominates the Global Laparoscopic Devices Market

    Research and Markets: Laparoscopic Devices - Global Strategic Business Report 2015: US Dominates the Global Laparoscopic Devices Market

  3. Research and Markets: Endoscopy Systems - Global Strategic Business Report 2015-2020 with Conmed, Cook Medical, Covidien, Ethicon Endo -Surgery & EndoChoice

    Research and Markets: Endoscopy Systems - Global Strategic Business Report 2015-2020 with Conmed, Cook Medical, Covidien, Ethicon Endo -Surgery & EndoChoice

  4. BioSpecifics Announces Appointment of Jennifer Chao and Jyrki Mattila, M.D., Ph.D. to Board of Directors

    BioSpecifics Announces Appointment of Jennifer Chao and Jyrki Mattila, M.D., Ph.D. to Board of Directors

  5. Meet Pharma's Newest Movers and Shakers, Driving M&A

    Meet Pharma's Newest Movers and Shakers, Driving M&A

  6. Meet Pharma's Newest Movers and Shakers, Driving M&A

    Meet Pharma's Newest Movers and Shakers, Driving M&A

  7. Health Care: 3 Picks in a More Expensive Sector

    Despite the sector looking slightly overvalued overall, we still see stocks that offer attractive valuations across the different industries.

  8. Actavis' Wide-Moat Transformation Offers Shareholder Rewards

    Product durability, diversification, and cost synergies support strong earnings growth for this undervalued wide-moat firm.

  9. The Market: Exaggerated Woes

    Endo Pharmaceuticals ENDP announced July 11 that it no longer expects to file a new drug application for its ketoprofen pain-relief patch by the first half of 2008 because of lackluster Phase III trial results. The drug candidate failed to show statistically significant results for pain relief in ...

  10. Credit Market Outlook: Tight Spreads Will Keep a Lid on Returns

    As credit spreads have tightened on a nearly continuous trend over the past year, they are becoming richly valued relative to their historical average.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.